STONY BROOK, N.Y. – July 2, 2019 – Applied DNA Sciences Inc. (NASDAQ: APDN) (“Applied DNA”, the “Company”), a leader in PCR-based DNA manufacturing for product authenticity and traceability solutions, announced today the signing of a five-year Agreement with Germany-based Montblanc-Simplo GMBH (“Montblanc”) for the provision of unique SigNature® DNA marks for individual Montblanc clients.

This Agreement culminates a rigorous 18-month product development and qualification program between Applied DNA and Montblanc for SigNature DNA with Beacon® in a range of specialist inks for use in the high-end range of Montblanc writing instruments. The SigNature DNA molecular tag provides the forensic evidence for traceability; Beacon is a covert screening feature of the SigNature DNA molecular tag, fluorescing only with complementary decryptant.

Under the terms of the Agreement, Applied DNA will supply a minimum number of its Signature DNA marks combined with Beacon for use by Montblanc clients on a 2-year exclusive basis.

Dr. James Hayward, president and CEO of Applied DNA, said, “We had a shared vision with Montblanc that our SigNature DNA with Beacon could be supplied to Montblanc clients who may wish to forensically prove a document had been signed using a personally unique molecular tag. We are pleased to announce this has been achieved and will soon be made available by Montblanc, initially to an exclusive list of their clients.”

Paolo Della Chiesa Poma, Junior Product Manager at Montblanc, said “We are very pleased to be able to offer this very unique and novel solution for our discerning clients following thorough and rigorous testing over many months.”

About Montblanc
Montblanc, synonymous with exquisite writing culture for the past 100 years, follows lasting values such as quality and traditional craftsmanship. Its uncompromising demands on shape, style, materials and workmanship are reflected in all its products. Founded in 1906 the Hamburg based company are renowned for their high quality and fashionable writing instruments, timepieces, leather goods amongst other high-end products.

About Applied DNA Sciences
Applied DNA is a provider of molecular technologies that enable supply chain security, anti-counterfeiting and anti-theft technology, product genotyping and DNA mass production for diagnostics and pre-clinical personalized medicine and therapeutics.

Applied DNA makes life real and safe by providing innovative, molecular-based technology solutions and services that can help protect products, brands, entire supply chains, and intellectual property of companies, governments and consumers from theft, counterfeiting, fraud and diversion.

Visit adnas.com for more information. Follow us on Twitter and LinkedIn. Join our mailing list.

Common stock listed on NASDAQ under the symbol APDN, and warrants are listed under the symbol APDNW.

Forward-Looking Statements
The statements made by Applied DNA in this press release may be “forward-looking” in nature within the meaning of the Private Securities Litigation Act of 1995. Forward-looking statements describe Applied DNA’s future plans, projections, strategies and expectations, and are based on assumptions and involve a number of risks and uncertainties, many of which are beyond the control of Applied DNA. Actual results could differ materially from those projected due to its history of net losses, limited financial resources, limited market acceptance, ability to maintain its NASDAQ listing and various other factors detailed from time to time in Applied DNA’s SEC reports and filings, including our Annual Report on Form 10-K filed on December 18, 2018 and our subsequent quarterly reports on Form 10-Q filed on February 7, 2019 and May 9, 2019, and other reports we file with the SEC, which are available at www.sec.gov. Applied DNA undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date hereof to reflect the occurrence of unanticipated events, unless otherwise required by law.

Investor contact: Sanjay M. Hurry, LHA Investor Relations, 212-838-3777, shurry@lhai.com
Media contact: Meryl Rader, 781-639-4924, meryl@cgprpublicrelations.com
Program contacts: Tony Benson, 44 (0) 7552 429341, tony.benson@adnas.com
Web: www.adnas.com
Twitter: @apdn